Wixela Inhub

Asthma, Chronic Obstructive Pulmonary Disease, Bronchospasm, Exercise-Induced + 1 more

Treatment

7 FDA approvals

20 Active Studies for Wixela Inhub

Treatment for

Asthma

What is Wixela Inhub

SalmeterolThe Generic name of this drug

Treatment SummaryFluticasone propionate is a drug used to treat inflammation. It is available as an inhaler, nasal spray, topical ointment, or cream. Fluticasone propionate was approved in 1990 and is commonly used to treat various inflammatory conditions.

Serevent Diskusis the brand name

image of different drug pills on a surface

Wixela Inhub Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Serevent Diskus

Salmeterol

1997

Approved as Treatment by the FDA

Salmeterol, otherwise called Serevent Diskus, is approved by the FDA for 7 uses including Asthma, Exercise-Induced and Asthma .

Asthma, Exercise-Induced

Asthma

Used to treat Asthma in combination with Fluticasone propionate

Exercise-Induced Bronchospasm

prophylaxis of Exercise-induced bronchospasm

Asthma

Used to treat Asthma in combination with Fluticasone propionate

Chronic Obstructive Pulmonary Disease

Helps manage Chronic Obstructive Pulmonary Disease (COPD)

Bronchospasm, Exercise-Induced

Effectiveness

How Wixela Inhub Affects PatientsWhen taken internally, fluticasone propionate works by activating certain receptors in the body and decreasing the number of eosinophils (a type of white blood cell) in the lungs. When applied topically, fluticasone propionate can cause the blood vessels in the skin to become narrower.

How Wixela Inhub works in the bodyFluticasone propionate has an unknown mechanism of action, but it is thought to reduce inflammation by targeting cell types and mediators. It can also activate specific receptors and reduce eosinophilia in the lungs of rats.

When to interrupt dosage

The proposed dosage of Wixela Inhub is contingent upon the indicated condition, comprising Sinusitis, Chronic Obstructive Pulmonary Disease (COPD) and Non-Allergic Rhinitis. The quantity of dosage fluctuates, as per the technique of delivery (e.g. Spray, metered - Nasal or Respiratory (inhalation)) featured in the following table.

Condition

Dosage

Administration

Bronchospasm, Exercise-Induced

, 0.05 mg, 0.021 mg, 0.014 mg, 0.05 mg/pump actuation, 0.014 mg/pump actuation, 0.025 mg/pump actuation, 0.01275 mg

, Oral; Respiratory (inhalation), Powder, metered, Powder, metered - Oral; Respiratory (inhalation), Respiratory (inhalation), Powder, Powder - Respiratory (inhalation), Powder - Oral; Respiratory (inhalation), Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Powder, metered - Respiratory (inhalation), Aerosol, Aerosol - Respiratory (inhalation)

Asthma, Exercise-Induced

, 0.05 mg, 0.021 mg, 0.014 mg, 0.05 mg/pump actuation, 0.014 mg/pump actuation, 0.025 mg/pump actuation, 0.01275 mg

Asthma

, 0.05 mg, 0.021 mg, 0.014 mg, 0.05 mg/pump actuation, 0.014 mg/pump actuation, 0.025 mg/pump actuation, 0.01275 mg

Chronic Obstructive Pulmonary Disease

, 0.05 mg, 0.021 mg, 0.014 mg, 0.05 mg/pump actuation, 0.014 mg/pump actuation, 0.025 mg/pump actuation, 0.01275 mg

Warnings

Wixela Inhub Contraindications

Condition

Risk Level

Notes

Status Asthmaticus

Do Not Combine

Chronic Obstructive Airway Disease

Do Not Combine

Not being treated with an inhaled corticosteroid

Do Not Combine

Asthma

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Salmeterol may interact with Pulse Frequency

There are 20 known major drug interactions with Wixela Inhub.

Common Wixela Inhub Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Major

The metabolism of (R)-warfarin can be decreased when combined with Salmeterol.

(S)-Warfarin

Major

The metabolism of (S)-Warfarin can be decreased when combined with Salmeterol.

Almotriptan

Major

The metabolism of Almotriptan can be decreased when combined with Salmeterol.

Aminophenazone

Major

The metabolism of Aminophenazone can be decreased when combined with Salmeterol.

Amitriptyline

Major

The metabolism of Amitriptyline can be decreased when combined with Salmeterol.

Wixela Inhub Toxicity & Overdose RiskNot much is known about the effects of fluticasone propionate in certain populations. Animal studies have shown that subcutaneous administration can cause birth defects in rats but oral administration does not have this effect. There are no known side effects when taken during pregnancy, although fluticasone propionate in human milk may affect growth and natural hormone production. Children and the elderly may be more sensitive to adverse effects. Fluticasone propionate is cleared from the body in the same way regardless of gender or race. Patients with liver problems should be monitored closely.

image of a doctor in a lab doing drug, clinical research

Wixela Inhub Novel Uses: Which Conditions Have a Clinical Trial Featuring Wixela Inhub?

There are 389 active clinical trials assessing the potential of Wixela Inhub to ameliorate Nasal Congestion, House Dust Mite Allergy and Atopic Dermatitis.

Condition

Clinical Trials

Trial Phases

Asthma

92 Actively Recruiting

Phase 1, Phase 4, Early Phase 1, Phase 2, Not Applicable, Phase 3

Chronic Obstructive Pulmonary Disease

77 Actively Recruiting

Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4

Bronchospasm, Exercise-Induced

0 Actively Recruiting

Asthma, Exercise-Induced

0 Actively Recruiting

Wixela Inhub Reviews: What are patients saying about Wixela Inhub?

5Patient Review

9/10/2022

Wixela Inhub for Controller Medication for Asthma

I had been taking Albuterol and Budesonide for a severe ASTHMA condition for over a year. I eventually had to use Albuterol 6-7 times per day to get any relief, and even then the relief amounted to only about 75%. I have now been on Wixela for almost one month and it has been very effective in completely relieving 99% of my Asthma with zero side effects.

2.7Patient Review

9/4/2022

Wixela Inhub for Controller Medication for Asthma

I was switched from Symbicort to Wixela and have been on it only a few days. Excessive coughing, lots of phlegm, Also I have lost my appetite. I have tried Trelegy successfully, am going back to it tonight.

2.3Patient Review

6/20/2022

Wixela Inhub for Controller Medication for Asthma

I experienced a lot of tightness in my chest, coughing, and shortness of breath while taking this medication. Additionally, the powder would sometimes stick to the back of my throat.

2Patient Review

6/8/2022

Wixela Inhub for Bronchospasm Prevention with COPD

Even half the recommended dosage leads to me coughing for most of the day. If I take a full dose, I can't sleep at night. The wheezing is incredibly loud and annoying. This medication really makes it hard to interact socially.

1.7Patient Review

6/6/2022

Wixela Inhub for Controller Medication for Asthma

My breathing has gotten worse since switching from Advair to Wixela

1.7Patient Review

8/21/2022

Wixela Inhub for Bronchospasm Prevention with COPD

VA switched me from symbicort to Wixela inhub. Since then my breathing is more difficult, not as effective. Wheezing and coughing more. I have since developed pneumonia. This was a cost cutting decision at the expense of our veterans' health, without question.

1.7Patient Review

9/19/2022

Wixela Inhub for Controller Medication for Asthma

I was on Advair for years with no issues, then my prescription changed to Wixela. I noticed a difference after only two days and by the fourth day, I could hardly breathe. I went back to Advair and felt better within 48 hours. There's no comparison between the two medications—Wixela is far inferior to Advair.

1.3Patient Review

6/16/2022

Wixela Inhub for Prevention of Bronchospasm with Chronic Bronchitis

Once I get below 20 puffs, it seems like the medication no longer works. This makes it difficult to breathe and is very frustrating. I've taken a few back to the pharmacy and they said the manufacturer would replace those 2 as a courtesy. However, I never had this issue with Advair and found it to be much more effective.

1Patient Review

3/25/2022

Wixela Inhub for Bronchospasm Prevention with COPD

I contacted my primary care provider through secure messaging on My health E Vet and told her how bad the new drug was. She got approval from the pharmacy to put me back on the symbicort.

1Patient Review

4/17/2022

Wixela Inhub for Bronchospasm Prevention with COPD

This drug caused my heart rate and blood pressure to spike dangerously. Inhaling it felt like trying to breathe in sand, and I coughed violently the whole time. After just one use, I could tell that this was a terrible medication; it's obviously only designed to save money for the VA while lineing the pockets of the company that produces it. Disgusting!

1Patient Review

10/3/2022

Wixela Inhub for Controller Medication for Asthma

Unfortunately, this medication caused me some problems. I ended up with a fat lip and gum irritation.

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about wixela inhub

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Wixela considered a steroid?

"Wixela Inhub is a combination of a corticosteroid and a long-acting beta-adrenergic agonist (LABA) indicated for twice-daily treatment of asthma in patients aged 4 years and older or maintenance treatment of airflow obstruction and reducing exacerbations."

Answered by AI

What are the side effects of Wixela Inhub?

"The most common side effects of Wixela Inhub when used to treat asthma include upper respiratory tract infection, throat irritation, hoarseness and voice changes, thrush in your mouth or throat, bronchitis, cough, headache, and nausea and vomiting. In children with asthma, infections in the ear, nose, and throat are especially common."

Answered by AI

Is Wixela same as Advair?

"Wixela Inhub is the first FDA approved generic version of Advair Diskus. It has the same active ingredients as Advair Diskus, which have been shown in clinical studies to improve lung function throughout the day for patients with asthma or COPD."

Answered by AI

What is Wixela prescribed for?

"The product is used to control symptoms caused by asthma or ongoing lung disease. It contains two medications: fluticasone and salmeterol."

Answered by AI

Clinical Trials for Wixela Inhub

Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+

All Sexes

Stanford, CA

Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.

Waitlist Available

Has No Placebo

Stanford UniversityJeff Swigris, DO, MSMinnesota Health Solutions

Have you considered Wixela Inhub clinical trials? We made a collection of clinical trials featuring Wixela Inhub, we think they might fit your search criteria.

Have you considered Wixela Inhub clinical trials? We made a collection of clinical trials featuring Wixela Inhub, we think they might fit your search criteria.